https://www.asco.org/file/asco-comments-ec-12-11-2018pdfASCO has submitted a statement for the record from ASCO Chief Executive Officer Clifford Hudis, MD, FACP, FASCO, to the House Energy and Commerce Committee’s Subcommittee on Health related to its recent hearing, “Implementing the 21st Century Cures Act: An Update from the Office of the National Coordinator.”
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
On Friday, December 7, President Trump signed into law a two-week Continuing Resolution (CR) to prevent a partial government shutdown.
While Congress was able to pass some of its Fiscal Year (FY) 2019 appropriations bills before the end of the 2018 fiscal year, it has not yet come to agreement on seven remaining appropriations bills, which fund a variety of federal departments and agencies, including the Food and Drug Administration (FDA). The CR will provide flat funding for those agencies until December 21, 2018, when Congress will need to take further action to fund them.
Members of Congress recently introduced bipartisan legislation, H.R. 6836, the CLINICAL TREATMENT Act, which would require Medicaid to cover the routine costs of care for patients with life threatening conditions who are enrolled in clinical trials. ASCO worked closely with Members of Congress to shape the legislation to address this gap in coverage for clinical trials.
Leaders from the ASCO State Affiliate Council met to discuss pressing issues in oncology, including drug pricing, Medicaid work requirements, changes to the Medicare physician fee schedule, and the role of pharmacy benefit managers (PBMs).
ASCO’s Policy Issue Briefs provide succinct overviews and relevant data on major policy issues impacting patients with cancer and the physicians who care for them. These briefs are designed to be especially helpful for journalists, offering background information on key issues across health policy today.
A bipartisan group of more than 100 members of the U.S. House of Representatives signed a letter to Centers for Medicare & Medicaid Services (CMS) Administrator Seema Verma urging the Agency to review and improve prior authorization practices under Medicare Advantage (MA). The letter, led by Rep. Ami Bera, MD (CA-7), and Rep. Phil Roe, MD (TN-1), cites concerns that MA beneficiaries may be encountering barriers to care due to “onerous and often unnecessary prior authorization requirements.”
President Trump recently signed a pair of bills into law aimed at increasing transparency with regard to drug prices in the United States. The Patient Right to Know Drug Prices Act (S. 2554) and the Know the Lowest Price Act (S. 2553) prohibit so-called "gag clauses," which prevent pharmacists from telling customers if they could save money by buying prescription drugs out-of-pocket rather than using their health insurance. S. 2554 applies to private health plans, while S. 2553 targets Medicare Part D and Medicare Advantage plans.
More than 100 ASCO volunteers from across the country came to Capitol Hill on September 25-26 for the 2018 ASCO Advocacy Summit, where they urged Congress to act on major policy priorities to support cancer research and ensure access to high-quality care for the millions of people in the United States with cancer.
ASCO applauds Congress for passing a $2 billion increase in funding for the National Institutes of Health (NIH), which will bring NIH's budget to a total of $39.1 billion and the National Cancer Institute's to a total of $6.147 billion.
The American Society of Clinical Oncology presented Representative Kevin Yoder (KS-03) with the 2018 Congressional Leadership Award today. Each year, ASCO presents this Award to a Member of Congress who has continuously supported legislation that promotes an improved practice environment for the oncology community and improves the quality of care for cancer patients
More than 100 oncology care providers from across the United States are heading to Capitol Hill September 25 – 26 to participate in the 2018 ASCO Advocacy Summit. Advocates will meet with Members of Congress and their staff to educate them on critical issues affecting individuals with cancer and their providers, and to encourage lawmakers to support cancer policies that will ensure access to high-quality, high-value cancer care.
Senator John McCain will lie in state in the U.S. Capitol Building today. The following ASCO statement pays tribute to his life-long service to our country.
The American Society of Clinical Oncology (ASCO) warns that Medicaid work requirements may hinder patients’ access to essential cancer care and reduce the already limited time physicians are able to spend with their patients. In a new position statement released today, ASCO also recommends that federal and state policymakers take specific steps to ensure that new Medicaid requirements will not harm patients with cancer.
ASCO submitted a statement to the U.S. House of Representatives Energy and Commerce Committee in conjunction with a subcommittee hearing on implementation of the Merit-Based Incentive Payment System (MIPS) under the Medicare Access and CHIP Reauthorization Act (MACRA).
On July 25, the U.S. House Energy and Commerce Committee held a hearing during which Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, Director of the National Cancer Institute (NCI) Norman Sharpless, MD, and Director of National Institutes of Health Francis Collins, MD, PhD, provided updates on how their respective agencies have been implementing the 21st Century Cures legislation.